Clinical Trials Logo

Clinical Trial Summary

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML


Clinical Trial Description

This trial will enroll approximately 140 randomized subjects 18 through 75 years of age at the time of randomization with primary refractory AML or relapsed AML (first or second untreated relapse) and eligible to receive induction chemotherapy as described. Randomization will be done at trial entry at a 1:1 ratio, and will be stratified by age (<60, ≥60 years) and disease status (primary refractory/early relapse ≤6 months, late relapse>6 months) and prior HSCT status. Treatment assignment received at randomization will be maintained during all induction and consolidation cycles. This trial will have the following sequential phases: screening, baseline, induction treatment and count recovery, response assessment, consolidation treatment (if remission is achieved), and follow-up for relapse and survival assessment. Subjects not achieving remission will continue to be followed for long-term trial endpoints such as disease progression and survival. Blinding will be maintained until database lock. All subjects will be followed for long-term outcomes until death or withdrawal of consent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05054543
Study type Interventional
Source Apollomics Inc.
Contact Zhejiang CrownMab Ltd.
Phone 0571-83521933
Email ClinicalTrialsChina@apollomicsinc.com
Status Recruiting
Phase Phase 3
Start date October 18, 2021
Completion date February 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Completed NCT01258816 - The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Phase 1
Terminated NCT02520427 - A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies Phase 1
Not yet recruiting NCT05805072 - Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients N/A
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Recruiting NCT05428969 - A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Phase 1/Phase 2
Recruiting NCT04839341 - Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients Phase 1
Recruiting NCT03631576 - CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) Phase 2/Phase 3